Splanchnic metabolism of triglycerides and other major substrates was studied in the postabsorptive state in normotriglyceridemic and hypertriglyceridemic human subjects who received ½ g of clofibrate four times daily for 3 wk. Transport in blood plasma of triglycerides produced in the splanchnic region was quantified by three methods: (a) measurement of the transsplanchnic gradient of 14 C-labeled triglycerides during constant intravenous infusion of [1-14 C] palmitate (b) chemical measurement of the transplanchnic gradient in concentration of triglycerides of very low density lipoproteins; and (c) determination of clearance of 14 Clabeled triglycerides in extrasplanchnic tissues. The first method measures only triglycerides derived from free fatty acids and the last two measure total splanchnic production. In hypertriglyceridemic subjects treated with clofibrate, average rates of total splanchnic production of triglycerides and production from free fatty acids were the same as those of comparable untreated subjects despite a consistent fall in plasma triglyceride levels. The hypotriglyceridemic effect of the drug was therefore accompanied by improved disposal of triglycerides in extrasplanchnic tissues. In treated normotriglyceridemic subjects, unlike their untreated counterparts, total splanchnic production was significantly higher than production from free fatty acids. Failure of clofibrate to reduce triglyceride levels in normotriglyceridemic subjects may have been related to increased total splanchnic production, coupled with improved extrasplanchnic disposal. A B S T R A C T Splanchnic metabolism of triglycerides and other major substrates was studied in the postabsorptive state in normotriglyceridemic and hypertriglyceridemic human subjects wh}o received A g of clofibrate four times daily for 3 wNk. Transport in blood plasma of triglycerides produced in the splanchnic region was quantified by three methods: (a) measurement of the transsplanchnic gradient of '4C-labeled triglycerides during constant intravenous infusion of [1-"C]palmitate (b) chemical measurement of the transsplanchnic gradient in concenltration of triglycerides of very low density lipoproteins; and (c) determination of clearance of 14C-labeled triglycerides in extrasplanchnic tissues. The first method measures only triglycerides derived from free fatty acids and the last two measure total splanchnic production. In hypertriglyceridemic subjects treated with clofibrate, average rates of total splanchulic production of triglycerides and productioni from free fatty acids were the same as those of conmparable untreated subjects despite a consistent fall in plasma triglyceride levels. The hvpotriglyceridemic effect of the drug was therefore accompanied by improved disposal of triglycerides in extrasplanchnic tissues. In treated normotriglyceridemic subjects, unlike their untreated counterparts, total splanchnic production wvas significantly higlher than prodluction from free fatty acids.
A B S T R A C T Splanchnic metabolism of triglycerides and other major substrates was studied in the postabsorptive state in normotriglyceridemic and hypertriglyceridemic human subjects wh}o received A g of clofibrate four times daily for 3 wNk. Transport in blood plasma of triglycerides produced in the splanchnic region was quantified by three methods: (a) measurement of the transsplanchnic gradient of '4C-labeled triglycerides during constant intravenous infusion of [1-"C] palmitate (b) chemical measurement of the transsplanchnic gradient in concenltration of triglycerides of very low density lipoproteins; and (c) determination of clearance of 14C-labeled triglycerides in extrasplanchnic tissues. The first method measures only triglycerides derived from free fatty acids and the last two measure total splanchnic production. In hypertriglyceridemic subjects treated with clofibrate, average rates of total splanchulic production of triglycerides and productioni from free fatty acids were the same as those of conmparable untreated subjects despite a consistent fall in plasma triglyceride levels. The hvpotriglyceridemic effect of the drug was therefore accompanied by improved disposal of triglycerides in extrasplanchnic tissues. In treated normotriglyceridemic subjects, unlike their untreated counterparts, total splanchnic production wvas significantly higlher than prodluction from free fatty acids. Failure of clofibrate to reduce triglyceride levels in normotriglyceridemic subjects may have been related
Portions of this xvork were presented at the Annual Meeting of the American Society for the Study of Arteriosclerosis, 10 November 1970 (1) , and at the Annual Meeting of the Canadian Society for Clinical Investigation, 26 January INTRODUCTION Clofibrate is widely used to treat primary hyperlipidemias (3) . It is especially effective in lowering serum triglyceride levels in endogenous hyperlipemias. Al- thouglh it has been suggested that clofibrate reduces serum triglycerides through effects on mobilization of free fatty acids (FFA) (4, 5) or on transport of endogenous trigly ceride fatty acids (TGFA)1 (6) (7) (8) (9) Table  I . Control subjects included 10 males and 5 females previously described (10) and 4 additional healthy men. Treated subjects included five healthy young men, three men, and a woman with primary endogenous hyperlipemia and a man with primary dysbetalipoproteinemia. The four control subjects not previously described and the treated subj ects had normal serum concentrations of albumin, globulins, total and direct bilirubin, glutamic-oxalacetic and glutamic-pyruvic transaminases, creatine phosphokinase, creatinine, protein-bound iodine, calcium, sodium, potassium, chloride, and bicarbonate. Each had normal hematological and urine analyses in addition to a normal chest roentgenogram. Two hypertriglyceridemic men of the treated group had borderline elevations of serum alkaline phosphatase (83 and 87 U/liter, normal range = 25-80), and one had an elevated level of serum uric acid (8.1 mg/100 ml).
Experimental procedutres. All subjects consumed a regular diet and maintained constant body weight (within 1 kg) during the 4-6 wk period of observation before the study of splanchnic metabolism. Normotriglyceridemic subjects, who are subsequently treated with clofibrate, were seen at weekly intervals on at least four occasions during the pretreatment period to obtain blood specimens (after a 12-15 h fast). Hypertriglyceridemic subjects had been followed in the clinic for prolonged periods and had taken no drugs known to affect serum lipids for at least 6 mo. In addition, they attended at least once to give a pretreatment fasting sample of blood. Each treated subject received 2 g of clofibrate daily in four divided doses given with meals and at bed time for 3 wk. Samples of blood (taken without stasis after the subjects had rested for about 15 min) were obtained in the postabsorptive state on four occasions during this period. Each treated subject took 0.5 g clofibrate approximately 1 h before sampling on days when fasting blood samples were obtained. All subjects were admitted to the metabolic research ward of the hospital for 3 days before the study and were placed on measured diets that were calculated to maintain weight. Mean food intake during this period was 1,170 kcal/m2 day (SD = 130) and contained the following distribution of calories: 18% protein, 42% fat, and 40% carbohydrate. The last meal, on the evening before the study, contained less than 5 g of fat with carbohydrate added to maintain constant caloric intake (10) . Clofibrate was continued up to the time of the study of splanchnic metabolism which began 15 h after this meal. Treated subjects received a 500 mg capsule of clofibrate 2 h before catheterization of the brachial artery and hepatic vein. Albumin-bound [1-14C] palmitate and indocyanine green were infused at a constant rate through an arm vein and simultaneous samples of arterial and hepatic venous blood were obtained at 20-to 30-min intervals between 50 and 240 min after-the start of the infusion (10) . Samples of expired air were obtained for measurement of 02 consumption and respiratory exchange ratio shortly before the first sampling of blood.
Analyses. These were the same as those described previously (10) with the following exceptions. Heptane extracts of plasma, obtained from treated subjects, were washed with dilute sulfuric acid by the method of Cenedella (5) to remove p-chlorophenoxyisobutyric acid (CPIB) before titration of FFA. The composition of FFA in the extract as determined by gas-liquid chromatography was unchanged by this procedure.
The plasma concentration of CPIB (Table III) NC, normotriglyceridemic males, controls; NRx, age-matched normotriglyceridemic males, treated with clofibrate; HC, hypertriglyceridemic males, controls; HRx, age-matched hypertriglyceridemic males, treated with clofibrate; AC, all controls (includes seven subjects from a previous study [10] in addition to NC and HC); ARx, all subjects treated with clofibrate (includes one hypertriglyceridemic female in addition to NRx and HRx). Significantly differenit fromn Pre-Rx (NR.x), P < 0.025. ¶ For each subject, the valtLie is that of a sinigle imeastirenmeiit obtained immediately before startinig treatmiienit with clofibrate. ** Significan-tly ditferenit fronm Pre-Rx (HRx), 1' < 0.025.
Mechanisms of Hypolipemic and Hyperketonemic Effects of Clofibrate
termined from a standar(d curve after correcting for recovery of CPIB added to plasma. To determinie the recovery of CPIB from plasma, 2 ml of stock isooctanie-ethanol, coIntaining 100 nmol of CPIB, was added to 0.4 ml of plasma and the results were compared with those obtained with the usual extraction of another sample of the same plasma. CPIB was prepared by the alkaline hydrolysis procedure of Cenedella (5) and extracted by shaking together equal volumes (100 ml) of aqueous CPIB (4 mM) and isooctaneethanol and then discarding the aqueous phase. The extract was washed once with 5 ml 0.05% H2SO4. Comparison of dry weight with titration of the stock solution showed the material to be essentially CPIB.
Pyruvic acid was measured in duplicate samples of neutralized perchloric acid extracts of wlhole blood by a microfluorometric modification of the method of Bticher, Czek, Lamprecht, and Latzko (12) .
Content of free amino acids in plasma deproteinized with sulfosalicylic acid (13) was determined by an automated two column ion-exchange technique using the Beckman model 121 (Beckman Instruments, Inc., Palo Alto, Calif.) amino acid analyzer (14) . Urinary excretion of urea was measured (15) on a 24 h sample of urine collected during the day before the study of splanchnic metabolism.
Very low density lipoproteins (VLDL) were isolated as described earlier (10) except in the studies of chemical composition reported in Table II in wN-hich the VLDL fractions were relayered under 0.15 M NaCl and centrifuged again for approximately 108 g-min. Samples of these VLDL were taken for determination of triglycerides, cholesterol, and protein (10) . In determining the composition of VLDL it was assumed that 70% of total cholesterol was esterified.
Lipoprotein electrophoresis was performed by the method of Noble (16 Calcuilationts. The equations used have been described (10) . Values for splanchnic conversion of ["C]FFA to plasma TGFA and VLDL-TGFA were calculated from a minimum of four sets of simultaneous arterial and hepatic venous blood samples obtained at 20-to 30-min intervals from 120 to 240 min after starting the isotopic infusion. In four male normotriglyceridemic control subjects in whom samples were obtained only during the period from 60 to 120 min after starting the infusion of radioisotope, the values obtained for conversion of [14C]FFA to [14C]TGFA were corrected for incomplete equilibration of plasma FFA with hepatic precursor pools of VLDL-TGFA by multiplying by a factor of 1.5 (see Fig. 4 in reference 10). From these values and the measured rate of splanchnic uptake of FFA, the rate of production of plasma TGFA derived from FFA ("radiochemical production") was computed (10) . These values underestimate splanchnic production of TGFA to the extent that these TGFA are derived from pools that are not in equilibrium w ith plasma FFA. Clearance of the plasma TGFA from the blood over a given interval of time was calculated from the formula:
-(RA,2 -RA,1) PX (t2 -tl) X 2(SAVLDL.TGFA,1 + SAVLDLTGFAI2) where RH radioactivity in TGFA of hepatic venous blood plasma, RA = radioactivity in TGFA of arterial blood plasma, (RH-RA)i; mean difference in radioactivity in TGFA between hepatic venous and arterial plasma during the interval of time (t2 -t1), PV = plasma volume, SAVLDL.-TG'SA specific activity of TGFA of VLDL, and EHPF; = mean estimated hepatic plasma flow. We have thus modified the formula of Boberg, Carlson, and Freyschuss (17) obtained from multiple simultaneous samples of hepatic venous and arterial blood. The time interval (t2 -tl) for individual calculations was restricted to periods when radioactivity in VLDL-TGFA was increasing at an approximately linear rate. Values obtained by this method, which provides an estimate of the rate at which triglycerides secreted from the splanchnic region are cleared from the blood in extrasplanchnic tissues, exceed those for "radiochemical production" to the extent that plasma TGFA are derived from precursors other than plasma FFA. Differences between groups were evaluated according to Snedecor and Cochran for both paired and unpaired samples (18) . Linear regressions were calculated by the method of least squares and their significance was evaluated from the correlation coefficient "r."
RESULTS-
Characteristics of groups of subjects Treated subjects resembled control subjects with respect to age, height, weight, body surface area, ponderal index, and volume of packed erythrocytes (Table I) . Control normotriglyceridemic men were taller than either treated normotriglyceridemic or control hypertriglyceridemic men (P < 0.05). The normotriglyceridemic subjects were younger than their hypertriglyceridemic counterparts and, in the control group, they had a higher mean ponderal index (P < 0.05). The difference between the volume of packed erythrocytes of control and treated hypertriglyceridemic male subjects may be attributed to repeated blood sampling in the latter.
Effect of clofibrate on blood lipids and carbohydrates before study of splanchnic metabolism Administration of clofibrate produced no consistent change in concentration of any of the measured lipid components of plasma in normotriglyceridemic subjects (Table II) . Concentrations of triglycerides and FFA fell significantly in hypertriglyceridemic subjects. In the four subjects in whom values for both were obtained, the average reduction of triglycerides was 44% (P < 0.05) and that of FFA was 24% (P < 0.05). Changes in cholesterol and phospholipid levels were variable. Data for hypertriglyceridemic subjects shown in Table  II included only the three male subjects for whom a complete set of values was available. The pretreatment values for these subjects are based on a single determination. The ratio of total cholesterol to triglyceride in VLDL (a2-VLDL plus P-VLDL) of the male hypertriglyceridemic subjects who had primary dysbetalipoproteinemia decreased from 1.47 to 0.89 (data not shown).' No consistent changes occurred in the composition of VLDL of normotriglyceridemic or of other. hypertriglyceridemic subjects. There were no significant changes in the concentration of 9-hydroxybutyrate (fi-OHB), glycerol, or glucose in blood after administration of clofibrate, but the concentration of lactate fell significantly in normotriglyceridemic men (P < 0.05).
Comparison of values obtained in treated subjects and controls during studies of splanchnic metabolism Oxygen metabolism. Plasma volume and splanchnic plasma flow, 02 consumption, and RQ were similar in 7,500+360 and 6,230+310 Amol/min * m' (P < 0.05 and P < 0.025), respectively. The fraction of total 02 uptake consumed in extrasplanchnic tissues of treated hypertriglyceridemic men, 72±2% (SEMI), was significantly lower than in treated normotriglyceridemic men, 83±1% (P < 0.025). Carbohydrate metabolism. There were no significant differences between age-and sex-matched treated and control subjects in arterial blood levels of glycerol, glucose, lactate, or pyrtivate (Table III) Metabolism of FFA. Levels of CPIB in plasma were about 0.4 mM in all treated subjects (Table III) . Plasma levels of FFA were significantly higher in normotriglyceridemic controls than in hlpertriglyceridemic con- control and treated subjects were similar. The turnover rate, splanchnic extraction fraction, and the fraction of the total net inflow transport of FFA taken up in the splanchnic vascular bed did not differ significantly in matched treated and control subjects (Table IV) . Total net inflow transport and total splanchnic uptake of FFA were also similar, indicating that clofibrate had no significant overall antilipolytic effect under the conditions of the study. However, net release of FFA from splanchnic tissues was significantly lower in treated normotriglyceridemic men than in normotriglyceridemic controls (P < 0.05) and in combined treated than in combined control subjects (P < 0.05).
The fraction of FFA converted to plasma TGFA in the splanchnic bed was attributable almost entirely to conversion of FFA to VLDL-TGFA and did not differ significantly between any of the control and treated groups of subjects (Table V) . The fraction of FFA converted to acetoacetate (AcAc) and to 14CO2 was significantly higher in treated than in control normotriglyceridemic men (P <0.05) and in combined treated than in combined control subjects (P < 0.025); however, conversion of FFA to P-OHB was the same in control and treated groups.
Metabolism of ketone bodies. The concentration of AcAc in arterial blood was significantly higher in treated than in control normotriglyceridermic men (Table VI) .
Although the mean values for arterial concentration of fi-OHB were higher in treated than in control normotriglyceridemic or hypertriglyceridemic subjects, only when treated and control groups were combined was the difference significant (P < 0.05). The mean specific activity of AcAc, expressed as percent of that of hepatic venous FFA, was lower in treated than in control normotriglyceridemic men; however, the difference was not of FFA* Values for extrasplanchnic clearance of TGFA from plasma correlated with values for radiochemical production in the combined control subjects (r = 0.71, P < 0.01, regression coefficient = 0.81 ) as well as in the combined treated subjects (r = 0.73, P < 0.025, regression coefficient = 1.76). Mean values for extrasplanchnic clearance of TGFA from plasma were almost the same as those for net splanchnic production of plasma TGFA from FFA in the 15 control subjects in whom estimates of both clearance and radiochemical production were possible (Table VII) (20, 21) and with data obtained in healthy young men starved for 3 days' (Table VIII) . (Table II) . Likewise, during the study of splanchnic metabolism, values for arterial concentrations, net inflow transport, and splanchnic uptake of FFA in treated normotriglvceridemic subjects wvere not significantly different from controls (Tables III and IV). In hypertriglyceridemic subjects, the concentration of FFA was significantly reduced during treatment. However, only a single control blood sample was taken before starting treatment in these subjects and, during the study of splanchnic metabolism, values for arterial concentrations, net inflow transport and splanchnic uptake of FFA differed by 10% or less from those observed in hypertriglyceridemic subjects who did not receive clofibrate. Only release of FFA from extrahepatic splanchnic tissues was lower in treated subjects. In spite of these largely negative observations, the possibility remains that clofibrate reduces overall transport of FFA in the fed state or under conditions unassociated with the stress of blood sampling.
In several reports, which have suggested that the level of FFA in plasma is reduced in the postabsorptive state in subjects taking clofibrate (23) (24) (25) , titration of FFA has included some CPIB so that a correction factor had to be applied. Bierman and associates (8) found similar levels of FFA (corrected for CPIB) before and during administration of clofibrate to hyperlipemic subjects. Assuming that CPIB contributes as much as 0.2 mM to titratable acidity in the hvperlipemic subjects studied by Ryan and Schwartz (7), the corrected values for FFA (0.63±0.04 mM) are not significantly lower than control values (0.68±0.06 m1M). The dose of clofibrate conventionally given to rats (0.25 g/100 g chow) results in levels of CPIB in plasma about twice those that we (Table III) and others (23) have observed in man. These higher levels are associated with reduced concentrations of FFA (5, 11) and glycerol (26) . Reduced plasma levels of FFA could contribute to the hypolipemic effect of clofibrate in this species provided that the turnover rate of FFA in the presence of clofibrate does not rise in proportion to the decrease in FFA concentration. The possibility that clofibrate may increase the rate of removal of FFA bv displacing fatty acid from stronger to weaker albumin-binding sites (27) received some support from the 19% higher turnover rate of FFA in treated than in control normotriglvceridemic men (0.05 < P < 0.10), but this was not observed in treated hypertriglyceridemic men and the difference in the combined treated group was small (Table IV) .
From available evidence, we conclude that the hypothesis that diminished hepatic uptake of FFA accounts for the hypolipemic effect of clofibrate in man remains unproved.
In the present study, we measured net splanchnic production of TGFA in both clofibrate-treated and control subjects by three methods, two of which (radiochemical and chemical production) were applied in an earlier study of splanchnic metabolism in normolipemic and hyperlipemic subjects (10) . Estimates of net splanchnic chemical production of VLDL-TGFA and of extrasplanchnic clearance of TGFA do not depend upon the assumption that FFA are the sole precursor of VLDL-TGFA.4 Despite consistent reduction of plasma TGFA levels in hypertriglyceridemic subjects given clofibrate, net splanchnic production of TGFA from FFA and clearance of TGFA in extrasplanchnic tissues were not significantly different from controls (Table VII) . Since triglyceride levels were reduced at a time that splanchnic production evidently was unchanged, it follows that utilization of triglycerides in extrasplanchnic tissues was more efficient. Net splanchnic production of TGFA from FFA in treated normotriglyceridemic subjects was also similar to that of controls; however, when production of TGFA was corrected for the contribution of precursors other than FFA,5 the mean value in treated subjects was 43% higher than that of controls. In normotriglyceridemic individuals given clofibrate, the relationship between specific activity of hepatic venous FFA and VLDL-TGFA indicated that almost 50% of VLDL-TGFA was derived from other precursors. This observation, which has been confirmed recently by Barter, Nestel, and Carroll (28) , is consistent with the finding that net splanchnic production of VLDL-TGFA in these subjects, as measured by chemically determined arteriovenous differences and by clearance of TGFA, was 30-40% greater than net splanchnic production of TGFA from FFA (Table VII) . In treated hypertriglyceridemic subjects, evidence for such an additional source of VLDL-TGFA was not obtained, since values for net splanchnic production of VLDL-TGFA from FFA and extrasplanchnic clearance of TGFA were similar. Mean plasma levels of TGFA were substantially unchanged in the normotriglyceridemic subjects during treatment despite evidence of increased transport of TGFA. Although the difference in transport between treated and ' Our evidence for this assumption in untreated subjects consuming diets containing about 42%o of calories from fat (10) has been extended by studies of Barter, Nestel, and Carroll (28) .
'Precursors of VLDL-TGFA other than FFA could be derived from hydrolysis of stored hepatic triglycerides (29) or from de llovo synthesis of fatty acids. Studies of Sodhi, Kudchodkar, and Horlick (30) (Table VII) .
The diet of their subjects was not carefully controlled. whereas our subjects ate measuired diets andl abstained from alcoholic beverages for 3 days before these measurements were made. The importanice of dietary preparation and other factors on the precursor-pool for VLDL-TGFA is emplhasized by the contribution of precursors other than FFA to this pool in association with high carbohydrate diets (28) and witlh hepatic steatosis from alcohol (28) or diabetes (29) . Clofibrate has a number of actions on hepatic metabolism in the rat ('33), but heretofore there has been virtually no information about its effect upon the human liver. ' We found that it does have important effects uponl splaicllhnic ilntermedial-y metabolism. Production of AcAc was approximately doubled in both normotriglyceridemic and hypertriglyceridemic subjects receiving the drug. In treated normotriglyceridermic subjects, about 30% of the AcAc appeared to be derived from sources other than FFA entering the liver (Table VI) . However, as in all untreated subjects, FFA accounted for almost all of the AcAc produced in hypertriglyceridemic subjects receiving clofibrate. Rates of ketogenesis are frequently related inversely to rates of secretion of VLDL from the liver (39) , but the fraction of palmitate secreted as VLDL-TGFA was virtually the same in clofibratetreated and control subjects (Table VI) , as was net production of TGFA derived from FFA. 'More 14CO2 was also produced from oxidation of FFA in the splanchnic region of treated subjects but, for reasons given elsewhere (10) , it cannot be concluded that more FFA was oxidized in the Krebs' cycle. An actual increase in oxidation of FFA to C02 and water is unlikely in view of the increased requirement for oxygen to form AcAc and the unchanged splanchnic 02 consumption of treated subjects.
Increased production of ketone bodies from acetate (40, 41) and pyruvate (41) has been observed in liver slices from rats fed clofibrate although no change has been observed in the concentration of AcAc in blood (42) . Enzymatic alterations that could lead to increased ketogenesis and to decreased cholesterogenesis in the liver of rats receiving clofibrate include reduced activity of hydroxymethylglutaryl-CoA reductase (40) and increased activity of mitochondrial acetoacetyl-CoA deacylase (42) . However, the pool of acetoacetyl-CoA from which cholesterol is synthesized mav be distinct from that leading to formation of AcAc (43) and the importance of enhanced activity of acetoacetyl-CoA deacylase in the increased production of ketone bodies from liver slices of clofibrate-treated rats has been questioned (41) . Recently, decreased synthesis of glycerolipids (26) and increased carnitine long-chain acyltransferase activity (44) have been demonstrated in the liver of rats given clofibrate. These alterations could lead to increased beta oxidation of fatty acids with augmented ketogenesis.
In our study clofibrate significantly increased the fraction of ketone bodies released from the splanchnic region as AcAc. This observation is consistent with higher mitochondrial ratio of NAD: NADH in the liver. An increase in hepatic content of NA D and in the ratio of NAD: NADH has been observed in rats receiving clofibrate (45) ; the latter change is consistent with our observations. The content of mitochondria in liver increases substantially in rats receiving a large dose of clofibrate (0.5 g/lOO g of diet) (46) . These mitochondria have normal oxidative activity and respiratory control. Such an increased oxidative capacity could minimize the more reduced state of mitochondrial pyridine nucleotides ordinarily associated with increased ketogenesis (47) .
Oxygen consumption of liver slices from rats treated with clofibrate is increased (48) and splanchnic oxygen consumption in men fasted for 3 days is about 50% higher than that observed in the postabsorptive state. Augmented ketogenesis could contribute to both of these changes. The similar splanchnic 02 consumption of our treated subjects and controls (Table III) may reflect the relatively minor change in ketogenesis. At any rate, it provides no support for the concept (48, 49) that the hypolipidemic effect of clofibrate is related to a state of hepatic hyperthyroidism.
Both splanchnic 02 consumption (Table III) and the fraction of FFA transported in the blood that was taken up in the splanchnic region (Table IV) were greater in hypertriglyceridemic than in normal subjects, whether or not clofibrate was given. Although these differences were significant only in the untreated groups, splanchnic 02 consumption was positively correlated with the total splanchnic uptake of FFA in control subjects (10) , treated subjects (r = 0.85, P < 0.01), and in all subjects combined (r = 0.61, P < 0.01). Furthermore, both 02 consumption and uptake of FFA in extrasplanchnic tissues were significantly lower in hypertriglyceridemic subjects than in normal subjects given clofibrate and these two variables were also positively correlated (r= 0.67, P < 0.05). The similar height, weight, and poInderal index of the two groups of treated subjects (Table  I) suggest that the distinct distributions of energy metabolism and substrate utilization are related to a fundamental metabolic disturbance in the hyperlipemic subjects. However, total 02 consumption was significantly lower in hypertriglyceridemic subjects, so that differences in the mass of major body tissues (liver, muscle, adipose tissue) in the two groups may explain these observations. Splanchnic metabolism of the major glycogenic amino acids was also systematically altered in both groups of treated subjects. Extraction fractions of amino acids entering the gluconeogenic pathway via pyruvate were consistently increased and their concentrations in arterial plasma were reduced. In treated normotriglyceridemic subjects, the extraction fraction of several other glycogenic amino acids was also increased. The concentration and splanchnic extraction of these amino acids resembled those of healthy men starved for 3 days (Table VIII) . In contrast, the lack of associated rise in arterial concentration of the branched-chain amino acids suggests that, unlike the situation in starved individuals, mobilization of amino acids from extrahepatic tissues was not altered substantially. Taken together, the augmented ketogenesis and splanchnic extraction Mechanismns of Hypolipemic and Hyperketonemic Effects of Clofibrate '215S7 fractions of amino acids and of lactate suggest that hepatic intermediary metabolism of postabsorptive subjects taking clofibrate resembled that of insulin-dependent diabetics (20) . These changes are consisitent with the hypothesis that treatment with clofibrate depletes liver glycogen with associated increases in ketogenesis and gluconeogenesis and, possibly, reduced cholesterogenesis.
